Skip to main content
Erschienen in:

11.09.2024 | Original Article

Functional Rehabilitation – an Integral Component for Quality of Life in the Holistic Management of COVID-19 Associated Mucormycosis

verfasst von: Akhilesh Kumar Pandey, Amanjot Kaur, Shubham Gaur, Aakash Kohli, Amit Goyal, Kapil Soni, Vidhu Sharma, Vidhi Jain, Taruna Yadav, Deepak Kumar, Poonam Elhence, Sanjeev Misra, Abhishek Anil, Ankita Chugh

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the quality of life in the post maxillectomy patients due to Coronavirus disease 2019 (COVID-19) associated Mucormycosis (CAM) following rehabilitation with obturators. The study also described the management and treatment outcomes of CAM patients. The study included 80 confirmed patients of CAM. The demographic profile, clinical presentations, predisposing and risk factors, and treatment outcomes were studied. Surgical and medical outcomes were expressed as percentages. After surgical debridement, 27 out of 80 patients were rehabilitated with obturators. The quality of life (QOL) of post debridement at 1 month (T1) vs. post 3 months (T2) of obturator use was measured using the oral health impact profile 14 (OHIP-14) scale. Maxillary sinus was involved in 98.75%, Ethmoid sinus in 51.25% and Sphenoid sinus in 26.25%. Surgical management involved Infrastructure maxillectomy in 56.25%, subtotal maxillectomy in 23.75%, and total maxillectomy with zygoma debridement in 20% of cases. Maxillary sinus debridement was done in 100%, Ethmoid sinus in 51.25%, and Sphenoid sinus in 26.25%. Medical management involved administration of intravenous Amphotericin B (total 3–5 g), and Posaconazole 300 mg OD for 3 months. The measured QOL using mean scores of each domain and the total score of OHIP-14 were lower at T2 (25.5 ± 6.809) compared to T1 (49.55 ± 9.822), (indicating better treatment outcomes) and were found to be statistically significant (P < 0.001). Early diagnosis, controlling risk factors, combined aggressive surgical and medical management reduces the morbidity and mortality of the patients. Early rehabilitation of the maxillectomy defects in CAM patients with temporary obturators mitigates deficient mastication and speech, thereby leading to improved function, aesthetics, and social well-being, and improving the overall QOL of these patients.
Literatur
1.
Zurück zum Zitat Shakrawal J, Sharma V, Goyal A, Kumar D, Meena S, Tiwari S et al (2023) Outcomes of transcutaneous retrobulbar amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19. Int Ophthalmol 43(6):1919–1926CrossRefPubMed Shakrawal J, Sharma V, Goyal A, Kumar D, Meena S, Tiwari S et al (2023) Outcomes of transcutaneous retrobulbar amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19. Int Ophthalmol 43(6):1919–1926CrossRefPubMed
2.
Zurück zum Zitat Aranjani JM, Manuel A, Razack HIA, Mathew ST (2021) COVID-19-associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLoS Negl Trop Dis 15(11):e0009921CrossRefPubMedPubMedCentral Aranjani JM, Manuel A, Razack HIA, Mathew ST (2021) COVID-19-associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLoS Negl Trop Dis 15(11):e0009921CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Gupta A, Kayarat B, Gupta N (2023) COVID-19 associated Mucormycosis (CAM): implications for perioperative physicians – A narrative review. Saudi J Anaesth 17(1):58–64CrossRefPubMedPubMedCentral Gupta A, Kayarat B, Gupta N (2023) COVID-19 associated Mucormycosis (CAM): implications for perioperative physicians – A narrative review. Saudi J Anaesth 17(1):58–64CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Gupta R, Kesavadev J, Krishnan G, Agarwal S, Saboo B, Shah M et al (2021) COVID-19 associated mucormycosis: a descriptive Multisite Study from India. Diabetes Metab Syndr 15(6):102322CrossRefPubMedPubMedCentral Gupta R, Kesavadev J, Krishnan G, Agarwal S, Saboo B, Shah M et al (2021) COVID-19 associated mucormycosis: a descriptive Multisite Study from India. Diabetes Metab Syndr 15(6):102322CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Sharma S, Grover M, Bhargava S, Samdani S, Kataria T (2021) Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 135(5):442–447CrossRefPubMed Sharma S, Grover M, Bhargava S, Samdani S, Kataria T (2021) Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 135(5):442–447CrossRefPubMed
6.
Zurück zum Zitat Singh AK, Singh R, Joshi SR, Misra A (2021) Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 15(4):102146CrossRefPubMedPubMedCentral Singh AK, Singh R, Joshi SR, Misra A (2021) Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 15(4):102146CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Zirpe K, Pote P, Deshmukh A, Gurav SK, Tiwari AM, Suryawanshi P (2021) A retrospective analysis of risk factors of COVID-19 Associated Mucormycosis and Mortality predictors: a single-center study. Cureus 13(10):e18718PubMedPubMedCentral Zirpe K, Pote P, Deshmukh A, Gurav SK, Tiwari AM, Suryawanshi P (2021) A retrospective analysis of risk factors of COVID-19 Associated Mucormycosis and Mortality predictors: a single-center study. Cureus 13(10):e18718PubMedPubMedCentral
8.
Zurück zum Zitat Chakravarty J, Gupta MK, Tilak R, Kumar R, Maurya RP, Kumar N et al (2022) COVID-19-associated mucormycosis: a clinico-epidemiological study. J Diabetes Complications 36(9):108284CrossRefPubMedPubMedCentral Chakravarty J, Gupta MK, Tilak R, Kumar R, Maurya RP, Kumar N et al (2022) COVID-19-associated mucormycosis: a clinico-epidemiological study. J Diabetes Complications 36(9):108284CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Gandhi A, Narula A, Chandra S, Agarwal D, Mehta A, Nayak S et al (2023) Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study. Int Ophthalmol 43(5):1571–1580CrossRefPubMed Gandhi A, Narula A, Chandra S, Agarwal D, Mehta A, Nayak S et al (2023) Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study. Int Ophthalmol 43(5):1571–1580CrossRefPubMed
10.
Zurück zum Zitat Skiada A, Pavleas I, Drogari-Apiranthitou M (2020) Epidemiology and diagnosis of mucormycosis: an update. J Fungi (Basel) 6(4):265CrossRefPubMed Skiada A, Pavleas I, Drogari-Apiranthitou M (2020) Epidemiology and diagnosis of mucormycosis: an update. J Fungi (Basel) 6(4):265CrossRefPubMed
11.
Zurück zum Zitat Watanabe A, So M, Mitaka H, Ishisaka Y, Takagi H, Inokuchi R et al (2022) Clinical features and mortality of COVID-19-Associated mucormycosis: a systematic review and Meta-analysis. Mycopathologia 187(2–3):271–289CrossRefPubMedPubMedCentral Watanabe A, So M, Mitaka H, Ishisaka Y, Takagi H, Inokuchi R et al (2022) Clinical features and mortality of COVID-19-Associated mucormycosis: a systematic review and Meta-analysis. Mycopathologia 187(2–3):271–289CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Bala K, Chander J, Handa U, Punia RS, Attri AK (2015) A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol 53(3):248–257CrossRefPubMed Bala K, Chander J, Handa U, Punia RS, Attri AK (2015) A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol 53(3):248–257CrossRefPubMed
13.
Zurück zum Zitat Rudrabhatla PK, Reghukumar A, Thomas SV (2022) Mucormycosis in COVID-19 patients: predisposing factors, prevention and management. Acta Neurol Belg 122(2):273–280CrossRefPubMed Rudrabhatla PK, Reghukumar A, Thomas SV (2022) Mucormycosis in COVID-19 patients: predisposing factors, prevention and management. Acta Neurol Belg 122(2):273–280CrossRefPubMed
14.
Zurück zum Zitat Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Singh B et al (2021) Mucormycosis in COVID-19 pandemic: risk factors and linkages. Curr Res Microb Sci 2:100057PubMedPubMedCentral Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Singh B et al (2021) Mucormycosis in COVID-19 pandemic: risk factors and linkages. Curr Res Microb Sci 2:100057PubMedPubMedCentral
15.
Zurück zum Zitat Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA (2020) A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep 29:22–24CrossRefPubMedPubMedCentral Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA (2020) A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep 29:22–24CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al (2021) Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384(8):693–704CrossRefPubMed Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al (2021) Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384(8):693–704CrossRefPubMed
17.
Zurück zum Zitat Singh R, Kumari A (2021) Nasal Microbiota Imbalance as a contributory link in the emergence of COVID-19 Associated Mucormycosis. ACS Infect Dis 7(8):2211–2213CrossRefPubMed Singh R, Kumari A (2021) Nasal Microbiota Imbalance as a contributory link in the emergence of COVID-19 Associated Mucormycosis. ACS Infect Dis 7(8):2211–2213CrossRefPubMed
18.
Zurück zum Zitat Gupta S, Goyal R, Kaore NM (2020) Rhino-Orbital-Cerebral mucormycosis: battle with the Deadly enemy. Indian J Otolaryngol Head Neck Surg 72(1):104–111CrossRefPubMed Gupta S, Goyal R, Kaore NM (2020) Rhino-Orbital-Cerebral mucormycosis: battle with the Deadly enemy. Indian J Otolaryngol Head Neck Surg 72(1):104–111CrossRefPubMed
19.
Zurück zum Zitat Pai V, Sansi R, Kharche R, Bandili SC, Pai B (2021) Rhino-orbito-cerebral mucormycosis. Pict Rev Insights Imaging 12(1):167CrossRef Pai V, Sansi R, Kharche R, Bandili SC, Pai B (2021) Rhino-orbito-cerebral mucormycosis. Pict Rev Insights Imaging 12(1):167CrossRef
20.
Zurück zum Zitat Saravanam PK, Thattarakkal VR, Arun A (2022) Rhino-Orbito-Cerebral mucormycosis: an audit. Indian J Otolaryngol Head Neck Surg 74:2686–2692CrossRefPubMed Saravanam PK, Thattarakkal VR, Arun A (2022) Rhino-Orbito-Cerebral mucormycosis: an audit. Indian J Otolaryngol Head Neck Surg 74:2686–2692CrossRefPubMed
21.
Zurück zum Zitat Werthman-Ehrenreich A (2021) Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 42:264.e5-264.e8 Werthman-Ehrenreich A (2021) Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 42:264.e5-264.e8
22.
Zurück zum Zitat Deutsch PG, Whittaker J, Prasad S (2019) Invasive and non-invasive fungal rhinosinusitis—a review and update of the evidence. Med (Kaunas) 55(7):319 Deutsch PG, Whittaker J, Prasad S (2019) Invasive and non-invasive fungal rhinosinusitis—a review and update of the evidence. Med (Kaunas) 55(7):319
23.
Zurück zum Zitat Nambiar M, Varma SR, Damdoum M (2021) Post-covid alliance-mucormycosis, a fatal sequel to the pandemic in India. Saudi J Biol Sci 28(11):6461–6464CrossRefPubMedPubMedCentral Nambiar M, Varma SR, Damdoum M (2021) Post-covid alliance-mucormycosis, a fatal sequel to the pandemic in India. Saudi J Biol Sci 28(11):6461–6464CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Rao KM, Pooja N (2022) Management of mucormycosis in Post COVID-19 patients and its outcome in a Tertiary Care Center: our experience. Indian J Otolaryngol Head Neck Surg 74:3344–3351CrossRefPubMedPubMedCentral Rao KM, Pooja N (2022) Management of mucormycosis in Post COVID-19 patients and its outcome in a Tertiary Care Center: our experience. Indian J Otolaryngol Head Neck Surg 74:3344–3351CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP (2018) Therapy of mucormycosis. J Fungi (Basel) 4(3):90CrossRefPubMed Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP (2018) Therapy of mucormycosis. J Fungi (Basel) 4(3):90CrossRefPubMed
26.
Zurück zum Zitat Stone NRH, Bicanic T, Salim R, Hope W (2016) Liposomal amphotericin B (AmBisome®): a review of the Pharmacokinetics, Pharmacodynamics, clinical experience and future directions. Drugs 76(4):485–500CrossRefPubMedPubMedCentral Stone NRH, Bicanic T, Salim R, Hope W (2016) Liposomal amphotericin B (AmBisome®): a review of the Pharmacokinetics, Pharmacodynamics, clinical experience and future directions. Drugs 76(4):485–500CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S et al (2020) A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clinical Microbiology and Infection 26(7):944.e9-944.e15 Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S et al (2020) A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clinical Microbiology and Infection 26(7):944.e9-944.e15
28.
Zurück zum Zitat Ali IE, Chugh A, Cheewin T, Hattori M, Sumita YI (2022) The rising challenge of mucormycosis for maxillofacial prosthodontists in the Covid-19 pandemic: a literature review. J Prosthodont Res 66(3):395–401CrossRefPubMed Ali IE, Chugh A, Cheewin T, Hattori M, Sumita YI (2022) The rising challenge of mucormycosis for maxillofacial prosthodontists in the Covid-19 pandemic: a literature review. J Prosthodont Res 66(3):395–401CrossRefPubMed
29.
Zurück zum Zitat Yusa K, Hemmi T, Ishikawa S, Yamanouchi H, Kasuya S, Sakurai H et al (2020) Rehabilitation after maxillectomy in patients with implant-retained obturator: a preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol 129(1):8–13CrossRefPubMed Yusa K, Hemmi T, Ishikawa S, Yamanouchi H, Kasuya S, Sakurai H et al (2020) Rehabilitation after maxillectomy in patients with implant-retained obturator: a preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol 129(1):8–13CrossRefPubMed
30.
Zurück zum Zitat Gaur V, Patel K, Palka L (2022) An implant-supported prosthetic rehabilitation of a patient with a bilateral subtotal maxillectomy defect secondary to rhino-orbital-cerebral mucormycosis: a clinical report of a graftless approach. J Prosthet Dent 128(1):101–106CrossRefPubMed Gaur V, Patel K, Palka L (2022) An implant-supported prosthetic rehabilitation of a patient with a bilateral subtotal maxillectomy defect secondary to rhino-orbital-cerebral mucormycosis: a clinical report of a graftless approach. J Prosthet Dent 128(1):101–106CrossRefPubMed
31.
Zurück zum Zitat Kumar L, Verma A, Pal US, Mattoo K, Algarni YA, Hassan SAB et al (2023) Influence of Prosthodontic Rehabilitation using zygomatic implants in Covid 19 related mucormycosis (Rhino-Orbital-Cerebral) Maxillectomy patients upon post-operative stress, anxiety and functional impairment: a prospective cohort study. Clin Interv Aging 18:1201–1219CrossRefPubMedPubMedCentral Kumar L, Verma A, Pal US, Mattoo K, Algarni YA, Hassan SAB et al (2023) Influence of Prosthodontic Rehabilitation using zygomatic implants in Covid 19 related mucormycosis (Rhino-Orbital-Cerebral) Maxillectomy patients upon post-operative stress, anxiety and functional impairment: a prospective cohort study. Clin Interv Aging 18:1201–1219CrossRefPubMedPubMedCentral
Metadaten
Titel
Functional Rehabilitation – an Integral Component for Quality of Life in the Holistic Management of COVID-19 Associated Mucormycosis
verfasst von
Akhilesh Kumar Pandey
Amanjot Kaur
Shubham Gaur
Aakash Kohli
Amit Goyal
Kapil Soni
Vidhu Sharma
Vidhi Jain
Taruna Yadav
Deepak Kumar
Poonam Elhence
Sanjeev Misra
Abhishek Anil
Ankita Chugh
Publikationsdatum
11.09.2024
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe 6/2024
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-024-05037-4

Neu im Fachgebiet HNO

Kopf-Hals-Tumore: Lebensqualität von Langzeitüberlebenden

Eine aktuelle Studie des Universitätsklinikums Erlangen verdeutlicht, dass Langzeitüberlebende von Kopf-Hals-Tumoren eine geringe Symptomlast aufweisen. Die am häufigsten auftretenden Beschwerden – Müdigkeit, Angstzustände, Schläfrigkeit und Schmerzen – sollten von den behandelnden Ärztinnen und Ärzten gezielt adressiert werden.

Schlafapnoe – es lag an einer verbogenen Nasenscheidewand

Tritt eine obstruktive Schlafapnoe vor allem in einer bestimmten Seitenlage auf, kann dies auch an einem verbogenen Nasenseptum liegen. Eine Septumplastik lindert die Beschwerden mitunter deutlich.

Wie gefährlich sind suspekte Veränderungen in der Mundhöhle?

Wie hoch ist das Risiko, dass sich aus einer bereits verdächtigen Veränderung der Mundschleimhaut ein Karzinom entwickelt? Ein US-Team hat dazu das Patientenregister der Universität San Francisco ausgewertet.

Chronische Rhinitis mit Botox lindern

Eine Injektion von Botulinumtoxin A in die Nasenmuscheln lindert Beschwerden einer chronischen Rhinitis für etwa zwei bis drei Monate. Vor allem Personen mit allergischer Rhinitis können davon profitieren.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.